JP2015525798A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015525798A5 JP2015525798A5 JP2015526648A JP2015526648A JP2015525798A5 JP 2015525798 A5 JP2015525798 A5 JP 2015525798A5 JP 2015526648 A JP2015526648 A JP 2015526648A JP 2015526648 A JP2015526648 A JP 2015526648A JP 2015525798 A5 JP2015525798 A5 JP 2015525798A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf antibody
- patient
- chemotherapeutic agent
- medicament
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680672P | 2012-08-07 | 2012-08-07 | |
| US61/680,672 | 2012-08-07 | ||
| US201261714438P | 2012-10-16 | 2012-10-16 | |
| US61/714,438 | 2012-10-16 | ||
| US201361760763P | 2013-02-05 | 2013-02-05 | |
| US61/760,763 | 2013-02-05 | ||
| PCT/US2013/053841 WO2014025813A1 (en) | 2012-08-07 | 2013-08-06 | Combination therapy for the treatment of glioblastoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017128609A Division JP2018008946A (ja) | 2012-08-07 | 2017-06-30 | 神経膠芽腫の治療のための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015525798A JP2015525798A (ja) | 2015-09-07 |
| JP2015525798A5 true JP2015525798A5 (enExample) | 2017-08-17 |
| JP6464085B2 JP6464085B2 (ja) | 2019-02-06 |
Family
ID=48985869
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526648A Active JP6464085B2 (ja) | 2012-08-07 | 2013-08-06 | 神経膠芽腫の治療のための併用療法 |
| JP2017128609A Withdrawn JP2018008946A (ja) | 2012-08-07 | 2017-06-30 | 神経膠芽腫の治療のための併用療法 |
| JP2019079205A Pending JP2019147812A (ja) | 2012-08-07 | 2019-04-18 | 神経膠芽腫の治療のための併用療法 |
| JP2021078365A Pending JP2021138704A (ja) | 2012-08-07 | 2021-05-06 | 神経膠芽腫の治療のための併用療法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017128609A Withdrawn JP2018008946A (ja) | 2012-08-07 | 2017-06-30 | 神経膠芽腫の治療のための併用療法 |
| JP2019079205A Pending JP2019147812A (ja) | 2012-08-07 | 2019-04-18 | 神経膠芽腫の治療のための併用療法 |
| JP2021078365A Pending JP2021138704A (ja) | 2012-08-07 | 2021-05-06 | 神経膠芽腫の治療のための併用療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150148585A1 (enExample) |
| EP (2) | EP3446709A1 (enExample) |
| JP (4) | JP6464085B2 (enExample) |
| KR (3) | KR20150038593A (enExample) |
| CN (1) | CN104507498A (enExample) |
| AU (3) | AU2013299724A1 (enExample) |
| BR (1) | BR112015002681A2 (enExample) |
| CA (1) | CA2880767A1 (enExample) |
| HK (1) | HK1204993A1 (enExample) |
| IL (2) | IL237028B (enExample) |
| MX (1) | MX360189B (enExample) |
| RU (1) | RU2015104001A (enExample) |
| SG (1) | SG11201500903XA (enExample) |
| WO (1) | WO2014025813A1 (enExample) |
| ZA (1) | ZA201500811B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6483082B2 (ja) | 2013-03-15 | 2019-03-13 | ジェネンテック， インコーポレイテッド | Ｐｄ−１及びｐｄ−ｌ１に関連する状態を治療するためのバイオマーカー及び方法 |
| US10617755B2 (en) * | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| AU2015217278B2 (en) * | 2014-02-14 | 2020-03-19 | Macrogenics, Inc. | Improved methods for the treatment of vascularizing cancers |
| US10780182B2 (en) | 2014-04-25 | 2020-09-22 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
| CA2946906A1 (en) * | 2014-05-07 | 2015-11-12 | Medimmune, Llc | Methods of using anti-ang2 antibodies |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3309174B1 (en) | 2014-07-11 | 2022-05-11 | Ventana Medical Systems, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
| EP3169801A1 (en) * | 2014-07-14 | 2017-05-24 | F. Hoffmann-La Roche AG | Diagnostic methods and compositions for treatment of glioblastoma |
| WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| JP7263669B2 (ja) * | 2017-06-12 | 2023-04-25 | レ ラボラトワール セルヴィエ | 併用療法を用いて脳腫瘍を処置する方法 |
| KR20250130443A (ko) * | 2017-06-12 | 2025-09-01 | 르 라보레또레 쎄르비에르 | 병용 요법을 사용한 뇌 종양 치료 방법 |
| BR112020017872A2 (pt) | 2018-03-02 | 2020-12-22 | Kodiak Sciences Inc. | Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| EP1238986B1 (en) | 1992-10-28 | 2008-06-25 | Genentech, Inc. | Use of Vascular endothelial cell growth factor antagonists |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| MX9800684A (es) | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| EP2338915A3 (en) | 1997-04-07 | 2011-10-12 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| US20030180714A1 (en) | 1999-12-15 | 2003-09-25 | Genentech, Inc. | Shotgun scanning |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| CA2561686C (en) | 2004-03-31 | 2014-12-02 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| EP2465870A1 (en) | 2005-11-07 | 2012-06-20 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
| US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| WO2007134050A2 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| SG175289A1 (en) * | 2009-04-20 | 2011-11-28 | Genentech Inc | Adjuvant cancer therapy |
| AU2011221229B2 (en) * | 2010-02-23 | 2015-06-18 | F. Hoffmann-La Roche Ag | Anti-angiogenesis therapy for the treatment of ovarian cancer |
| EP4159226A1 (en) * | 2010-08-24 | 2023-04-05 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| US20120114638A1 (en) * | 2010-11-08 | 2012-05-10 | John Boylan | Combination therapy |
-
2013
- 2013-08-06 CN CN201380040940.7A patent/CN104507498A/zh active Pending
- 2013-08-06 CA CA2880767A patent/CA2880767A1/en not_active Abandoned
- 2013-08-06 WO PCT/US2013/053841 patent/WO2014025813A1/en not_active Ceased
- 2013-08-06 HK HK15105936.9A patent/HK1204993A1/xx unknown
- 2013-08-06 EP EP18178511.4A patent/EP3446709A1/en not_active Withdrawn
- 2013-08-06 BR BR112015002681A patent/BR112015002681A2/pt not_active Application Discontinuation
- 2013-08-06 MX MX2015001627A patent/MX360189B/es active IP Right Grant
- 2013-08-06 EP EP13748450.7A patent/EP2882454B1/en not_active Revoked
- 2013-08-06 RU RU2015104001A patent/RU2015104001A/ru not_active Application Discontinuation
- 2013-08-06 AU AU2013299724A patent/AU2013299724A1/en not_active Abandoned
- 2013-08-06 KR KR20157005660A patent/KR20150038593A/ko not_active Ceased
- 2013-08-06 SG SG11201500903XA patent/SG11201500903XA/en unknown
- 2013-08-06 KR KR1020187002046A patent/KR20180011356A/ko not_active Ceased
- 2013-08-06 KR KR1020197020608A patent/KR20190088571A/ko not_active Ceased
- 2013-08-06 JP JP2015526648A patent/JP6464085B2/ja active Active
-
2015
- 2015-02-01 IL IL237028A patent/IL237028B/en active IP Right Grant
- 2015-02-04 ZA ZA2015/00811A patent/ZA201500811B/en unknown
- 2015-02-06 US US14/616,505 patent/US20150148585A1/en not_active Abandoned
-
2016
- 2016-10-13 AU AU2016244262A patent/AU2016244262B2/en not_active Ceased
-
2017
- 2017-06-30 JP JP2017128609A patent/JP2018008946A/ja not_active Withdrawn
-
2018
- 2018-10-23 AU AU2018253461A patent/AU2018253461A1/en not_active Abandoned
- 2018-12-12 IL IL263661A patent/IL263661A/en unknown
-
2019
- 2019-04-18 JP JP2019079205A patent/JP2019147812A/ja active Pending
- 2019-04-29 US US16/397,104 patent/US20200086139A1/en not_active Abandoned
-
2021
- 2021-05-06 JP JP2021078365A patent/JP2021138704A/ja active Pending